The prevalence of estrogen receptor-negative breast cancer in Ethiopia

BMC Cancer

Bekuretsion Yonas²  Pietro Trocchi⁷  Tufa Gemechu²  Andreas Stang⁵  Christoph Thomssen⁴  Solomon Bogale³  Anne Reeler⁸  Erdme Knauf⁴  Martina Vetter⁴  Ahmedin Jemal¹  Tigeneh Wondemagegnehu³  Abreha Aynalem³  Assefa Mathewos³  Eva Johanna Kantelhardt⁶ 

[1]American Cancer Society, Atlanta, USA

[2]Department of Pathology, Addis-Ababa-University, Addis Ababa, Ethiopia

[3]Radiotherapy Center, Addis-Ababa-University, Addis Ababa, Ethiopia

[4]Department of Gynecology, Martin-Luther-University, Halle an der Saale, Germany

[5]Department of Epidemiology, Boston University, School of Public Health, Boston, MA, USA

[6]Department of Gynecology and Institute of Clinical Epidemiology, Martin-Luther-University, Ernst-Grube Str. 40, 06097 Halle an der Saale, Germany

[7]Institute of Clinical Epidemiology, Martin-Luther-University, Halle an der Saale, Germany

[8]Axios International, Paris, France

关键词: Prognostic factors;    Ethiopia;    Africa;    Breast neoplasms;   

Others  :  1117978
DOI  :  10.1186/1471-2407-14-895

 received in 2014-06-12, accepted in 2014-11-20,  发布年份 2014

【 摘 要 】

Background

In contrast with breast cancers (BCs) in other parts of the world, most previous studies reported that the majority of BCs in sub-Saharan Africa are estrogen-receptor (ER) negative. However, a recent study using the US SEER database showed that the proportion of ER-negative BC is comparable between US-born blacks and West-African born blacks but substantially lower in East African-born blacks, with over 74% of patients Ethiopians or Eritreans. In this paper, we provide the first report on the proportion of ER-negative BC in Ethiopia, and the relation to progesterone-receptor (PgR) status.

Methods

We analysed 352 female patients with ER results available out of 1208 consecutive female BC patients treated at Addis Ababa-University Hospital, Ethiopia, from June 2005 through December 2010. The influences of age, stage, and histology on the probability of ER-negative tumours were assessed by a log-linear regression model.

Results

Of the 352 patients, only 35% were ER-negative. The proportion of ER-negative tumours decreased with advancing age at diagnosis and was not affected by histology or stage. For age, the proportion decreased by 6% for each additional 5 years (stage-adjusted prevalence ratio PR = 0.94, 95% CI: 0.89–1.00). About 31% were ER- and PgR-negative, and 69% were ER- and/or PgR-positive.

Conclusions

Contrary to most previous reports in other parts of sub-Saharan Africa, the majority of patients in Ethiopia are ER-positive rather than ER-negative. These findings are in line with low proportions of ER-negative BCs from East African immigrants within the SEER database, and they have clinical implications for management of BC patients in Ethiopia and other parts of sub-Saharan Africa where ER-status is not ascertained as part of routine management of the disease. Since the majority of patients showed ER-positive BC, Tamoxifen-therapy should be given to all patients even with unknown ER status.

【 授权许可】

   
2014 Kantelhardt et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bird PA, Hill AG, Houssami N: Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol 2008, 15:1983-1988.
• [2]Mbonde MP, Amir H, Akslen LA, Kitinya JN: Expression of oestrogen and progesterone receptors, Ki67, p53 and BCL-2 proetins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African Population. East African Medical Journal 2001, 78:360-365.
• [3]Nalwoga H, Arnes JB, Wabinga H, Akslen LA: Frequency of the basal-like phenotype in African breast cancer. APMIS 2007, 115:1391-1399.
• [4]Huo D, Ikpatt F, Khramtsov A, Dangou J, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI: Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 2009, 27:4515-4521.
• [5]Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, Takyi V, Braman M, Quayson SE, Zarbo R, Wicha M, Newman L: African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer 2010, 116:4926-4932.
• [6]Pang J, Toy KA, Griffith KA, Awuah B, Quayson S, Newman LA, Kleer CG: Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression. Breast Cancer Res Treat 2012, 135:59-66.
• [7]Ohene-Yeboah M, Adjei E: Breast cancer in Kumasi, Ghana. Ghana Med J 2012, 46:8-13.
• [8]Ly M, Antoine M, Dembele AK, Levy P, Rodenas A, Toure BA, Badiaga Y, Dembele BK, Bagayogo DC, Diallo YL, Kone AA, Callard P, Bernaudin J, Diallo DA: High incidence of triple-negative tumors in Sub-Saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian Women Seen in a Bamako University Hospital. Oncology 2012, 83:257-263.
• [9]Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE: Immunohistochemical and molecular subtypes of Breast Cancer in Nigeria. Br Can Res Tr 2008, Colume 110:183-188.
• [10]Adjei EK, Owusu-Afriyie O, Awuah B, Stalsberg H: Hormone receptors and Her2 expression in breast cancer in sub-Saharan Africa. A comparative study of biopsies from Ghana and Norway. Breast J 2014, 20:308-311.
• [11]Roy I, Othieno E: Breast carcinoma in Uganda: microscopic study and receptor profile of 45 cases. Arch Pathol Lab Med 2011, 135:194-199.
• [12]McCormack VA, Joffe M, van den Berg E, Broeze N, Dos Santos SI, Romieu I, Jacobson JS, Neugut AI, Schuz J, Cubasch H: Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series. Breast Cancer Res 2013, 15:R84. BioMed Central Full Text
• [13]Jemal A, Fedewa SA: Is the prevalence of ER-negative breast cancer in the US higher among Africa-born than US-born black women? Breast Cancer Res Treat 2012, 135:867-873.
• [14]Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG: Cancer Registration: Principles and Methods: IARC Scientific Publication No. 95. Lyon France: World Health Organisation; 1991.
• [15]Edge SB: AJCC Cancer Staging Manual. 7th edition. New York: Springer; 2010.
• [16]Sobin L, Gospodarowicz M, Wittekind C: TNM Classification of malignant tumors. 7th edition. Hoboken: John Wiley & Sons, Inc; 2009. NJ, USA: John Wiley & Sons, Inc.; 2009
• [17]European network of cancer registries (ENCR): Condensed TNM for Coding the Extent of Disease. ENCR RECOMMENDATIONS. [http://www.encr.eu/images/docs/recommendations/extentofdisease.pdf webcite]
• [18]Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn H: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18:1133-1144.
• [19]Fernando IN, Powles TJ, Dowsett M, Ashley S, McRobert L, Titley J, Ormerod MG, Sacks N, Nicolson MC, Nash A: Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry. Virchows Arch 1995, 426:155-161.
• [20]Makris A, Allred DC, Powles TJ, Dowsett M, Fernando IN, Trott PA, Ashley SE, Ormerod MG, Titley JC, Osborne CK: Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat 1997, 44:65-74.
• [21]Pegolo E, Machin P, Riosa F, Bassini A, Deroma L, Di Loreto C: Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination. Cancer Cytopathol 2012, 120:196-205.
• [22]Jabbour MN, Massad CY, Boulos FI: Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma. Breast Cancer Res Treat 2012, 135:29-37.